scholarly journals Development and validation of a circulating microRNA panel for the early detection of breast cancer

2022 ◽  
Author(s):  
Ruiyang Zou ◽  
Sau Yeen Loke ◽  
Yew Chung Tang ◽  
Heng-Phon Too ◽  
Lihan Zhou ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Early Stage ◽  
False Positive Rate ◽  
Area Under The Curve ◽  
Circulating Microrna ◽  
Serum Samples ◽  
Asian Populations ◽  
Multi Center Study

Abstract Background Mammography is widely used for breast cancer screening but suffers from a high false-positive rate. Here, we perform the largest comprehensive, multi-center study to date involving diverse ethnic groups, for the identification of circulating miRNAs for breast cancer screening. Methods This study had a discovery phase (n = 289) and two validation phases (n = 374 and n = 379). Quantitative PCR profiling of 324 miRNAs was performed on serum samples from breast cancer (all stages) and healthy subjects to identify miRNA biomarkers. Two-fold cross-validation was used for building and optimising breast cancer-associated miRNA panels. An optimal panel was validated in cohorts with Caucasian and Asian samples. Diagnostic ability was evaluated using area under the curve (AUC) analysis. Results The study identified and validated 30 miRNAs dysregulated in breast cancer. An optimised eight-miRNA panel showed consistent performance in all cohorts and was successfully validated with AUC, accuracy, sensitivity, and specificity of 0.915, 82.3%, 72.2% and 91.5%, respectively. The prediction model detected breast cancer in both Caucasian and Asian populations with AUCs ranging from 0.880 to 0.973, including pre-malignant lesions (stage 0; AUC of 0.831) and early-stage (stages I–II) cancers (AUC of 0.916). Conclusions Our panel can potentially be used for breast cancer screening, in conjunction with mammography.

Breast Cancer Screening in Older Women—Current Evidence and Future Perspectives

2015 ◽  
Vol 11 (01) ◽  
pp. 34
Author(s):  
Nienke A de Glas ◽  
Gerrit-Jan Liefers ◽  
◽  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Older Women ◽  
Breast Cancer Screening ◽  
Early Stage ◽  
Developed Countries ◽  
Population Based ◽  
Current Data ◽  
Current Evidence ◽  
Strong Increase

As populations of developed countries are aging, the number of older women with breast cancer will strongly increase. Randomized controlled trials in breast cancer screening rarely included patients over the age of 68. As a consequence, there is no solid evidence for beneficial effects of breast cancer screening in older women. In a recent observational study, we showed that the implementation of screening in women aged 70–75 in the Netherlands resulted in a strong increase of the incidence of early-stage breast cancer, while the incidence of advanced stage breast cancer barely decreased. Hence, current data do not support population-based screening in women over the age of 70.

scholarly journals Feasibility Study of a Randomised Trial of Ovarian Cancer Screening among the General Population

1994 ◽  
Vol 1 (4) ◽  
pp. 209-214 ◽  
Author(s):  
C A Parkes ◽  
D Smith ◽  
N J Wald ◽  
T H Bourne
Keyword(s):  
Breast Cancer ◽  
Ovarian Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Screening Test ◽  
False Positive Rate ◽  
Randomised Trial ◽  
Doppler Imaging ◽  
Colour Doppler ◽  
Ovarian Cancer Screening

To determine the feasibility of a randomised trial of ovarian cancer screening among women attending a breast cancer screening centre. Randomised controlled trial of ovarian cancer screening using transvaginal ultrasonography as a primary screening test and colour Doppler imaging as a secondary screening test in the screened group and no intervention in the control group. Reading breast cancer screening centre (United Kingdom). 8678 women, without a bilateral oophorectomy or hysterectomy, aged between SO and 64 attending for NHS breast cancer screening between September 1989 and February 1993. Uptake of ovarian cancer screening among eligible women and the screening false positive rate (considered as the referral rate to a gynaecologist for surgical intervention). −82% (7124/8678) of eligible women agreed to join the trial and were randomly allocated in equal numbers to each arm of the trial. 3280 women had an initial scan. The false positive rate after ultrasonography alone was 2·9% (86/2952), but this dropped to 0·5% after colour Doppler as a secondary screening test. One stage I primary ovarian cancer was detected at screening in a 58 year old women. A randomised trial of ovarian cancer screening using ultrasonography and colour Doppler imaging is feasible and acceptable among women attending a breast cancer screening centre. The results indicate that the expected odds of being affected given a positive result in the general population would be about 1:12. A full randomised trial of ovarian cancer screening with mortality as the end point is needed to assess whether screening reduces mortality from this disease. A multicentre European trial is currently in progress.

scholarly journals Breast cancer screening in average-risk women: towards personalized screening

2019 ◽  
Vol 92 (1103) ◽  
pp. 20190660 ◽  
Author(s):  
Almir GV Bitencourt ◽  
Carolina Rossi Saccarelli ◽  
Christiane Kuhl ◽  
Elizabeth A Morris
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Task Force ◽  
Early Stage ◽  
Breast Cancer Mortality ◽  
Mammographic Screening ◽  
Screening Strategy ◽  
Average Risk ◽  
Early Stage Disease

Breast cancer screening is widely recognized for reducing breast cancer mortality. The objective in screening is to diagnose asymptomatic early stage disease, thereby improving treatment efficacy. Screening recommendations have been widely debated over the past years and controversies remain regarding the optimal screening frequency, age to start screening, and age to end screening. While there are no new trials, follow-up information of randomized controlled trials has become available. The American College of Physicians recently issued a new guidance statement on screening for breast cancer in average-risk women, with similar recommendations to the U.S. Preventive Services Task Force and to European guidelines. However, these guidelines differ from those ofother American specialty societies. The variations reflect differences in the organizations’ values, the metrics used to evaluate screening results, and the differences in healthcare organization (individualized or state-organized healthcare). False-positive rates and overdiagnosis of biologically insignificant cancer are perceived as the most important potential harms associated with mammographic screening; however, there is limited evidence on their actual consequences. Most specialty societies agree that physicians should offer mammographic screening at age 40 years for average-risk women and discuss its benefits and potential harms to achieve a personalized screening strategy through a shared decision-making process.

scholarly journals Increased Circulating MicroRNA-155 as a Potential Biomarker for Breast Cancer Screening: A Meta-Analysis

Molecules ◽  
2014 ◽  
Vol 19 (5) ◽  
pp. 6282-6293 ◽  
Author(s):  
Faliang Wang ◽  
Jinchao Hou ◽  
Wei Jin ◽  
Jiaqiu Li ◽  
Yongfang Yue ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Meta Analysis ◽  
Circulating Microrna ◽  
Potential Biomarker

scholarly journals Observational Study to Evaluate the Clinical Efficacy of Thermalytix for Detecting Breast Cancer in Symptomatic and Asymptomatic Women

2020 ◽  
pp. 1472-1480
Author(s):  
Siva Teja Kakileti ◽  
Himanshu J. Madhu ◽  
Lakshmi Krishnan ◽  
Geetha Manjunath ◽  
Sudhakar Sampangi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Observational Study ◽  
Breast Cancer Screening ◽  
Age Groups ◽  
Nipple Discharge ◽  
Area Under The Curve ◽  
Ground Truth ◽  
Breast Malignancy ◽  
Asymptomatic Women

PURPOSE To evaluate the sensitivity and specificity of Thermalytix, an artificial intelligence–based computer-aided diagnostics (CADx) engine, to detect breast malignancy by comparing the CADx output with the final diagnosis derived using standard screening modalities. METHODS This multisite observational study included 470 symptomatic and asymptomatic women who presented for a breast health checkup in two centers. Among them, 238 women had symptoms such as breast lump, nipple discharge, or breast pain, and the rest were asymptomatic. All participants underwent a Thermalytix test and one or more standard-of-care tests for breast cancer screening, as recommended by the radiologists. Results from Thermalytix and standard modalities were obtained independently in a blinded fashion for comparison. The ground truth used for analysis (normal or malignant) was the final impression of an expert clinician based on the symptoms and the available reports of standard modalities (mammography, ultrasonography, elastography, biopsy, fine-needle aspiration cytology, and so on). RESULTS For the 470 women, Thermalytix resulted in a sensitivity of 91.02% (symptomatic, 89.85%; asymptomatic, 100%) and specificity of 82.39% (symptomatic, 69.04%; asymptomatic, 92.41%) in detection of breast malignancy. Thermalytix showed an overall area under the curve (AUC) of 0.90, with an AUC of 0.82 for symptomatic and 0.98 for asymptomatic women. CONCLUSION High sensitivity and high AUC of Thermalytix in women of all age groups demonstrates the efficacy of the tool for breast cancer screening. Thermalytix, with its automated scoring and image annotations of potential malignancies and vascularity, can assist the clinician in better decision making and improve quality of care in an affordable and radiation-free manner. Thus, we believe Thermalytix is poised to be a promising modality for breast cancer screening.

scholarly journals Coverage determinants of breast cancer screening in Flanders: an evaluation of the past decade

2020 ◽  
Vol 19 (1) ◽  
Author(s):  
L. Ding ◽  
S. Jidkova ◽  
M. J. W. Greuter ◽  
K. Van Herck ◽  
M. Goossens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Dental Care ◽  
Screening Program ◽  
Early Stage ◽  
Target Population ◽  
Coverage Rate ◽  
Younger Age ◽  
Screening Coverage

Abstract Background Breast cancer (BC) is the most common cancer in women in the developed world. In order to find developing cancers in an early stage, BC screening is commonly used. In Flanders, screening is performed in and outside an organized breast cancer screening program (BCSP). However, the determinants of BC screening coverage for both screening strategies are yet unknown. Objective To assess the determinants of BC screening coverage in Flanders. Methods Reimbursement data were used to attribute a screening status to each woman in the target population for the years 2008–2016. Yearly coverage data were categorized as screening inside or outside BCSP or no screening. Data were clustered by municipality level. A generalized linear equation model was used to assess the determinants of screening type. Results Over all years and municipalities, the median screening coverage rate inside and outside BCSP was 48.40% (IQR: 41.50–54.40%) and 14.10% (IQR: 9.80–19.80%) respectively. A higher coverage rate outside BSCP was statistically significantly (P < 0.001) associated with more crowded households (OR: 3.797, 95% CI: 3.199–4.508), younger age, higher population densities (OR: 2.528, 95% CI: 2.455–2.606), a lower proportion of unemployed job seekers (OR: 0.641, 95% CI: 0.624–0.658) and lower use of dental care (OR: 0.969, 95% CI: 0.967–0.972). Conclusion Coverage rate of BC screening is not optimal in Flanders. Women with low SES that are characterized by younger age, living in a high population density area, living in crowded households, or having low dental care are less likely to be screened for BC in Flanders. If screened, they are more likely to be screened outside the BCSP.

Sign in / Sign up

Export Citation Format

Share Document